why choose us

First received: April 11, 2023

Clinical Trial: A Study of PMG1015 Injection in Idiopathic Pulmonary Fibrosis Subjects

Study Status: Completed

Recruit Status: RECRUITING

Condition: IPF

Study Type: INTERVENTIONAL


Official Title: A Phase Ib, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PMG1015 Injection After Multiple Ascending Doses in Subjects

Brief Summary: Idiopathic Pulmonary Fibrosis (IPF): It is a progressive and fatal fibrosing interstitial lung disease of unknown etiology, with a median survival of only 2 to 3 years.Epidemiology of IPF (with reference to the international epidemiological studies due to the lack of accurate epidemiological data in China): the incidence was 2 to 30 per 100,000 person years, and the prevalence was 10 to 60 per 100,000.More males suffer from IPF than females.In population aged more than 65 years, the estimated prevalence was up to…

Read more